• Something wrong with this record ?

Valsartan v léčbě fibrilace síní?
[Valsartan for prevention of recurrent atrial fibrillation]

Disertori M, Latini R, Barlera S, Franzosi MG, Staszewsky L, Maggioni AP, Lucci D, Di Pasquale G, Tognoni G.

. 2009 ; 3 (5) : 38-39.

Language Czech Country Czech Republic

Document type Multicenter Study

Persistent link   https://www.medvik.cz/link/bmc09002365

Atrial fibrillation is the most common cardiac arrhythmia, and no current therapy is ideal for control of this condition. Experimental studies suggest that angiotensin II-receptor blockers (ARBs) can influence atrial remodeling, and some clinical studies suggest that they may prevent atrial fibrillation. METHODS: We conducted a large, randomized, prospective, placebo-controlled, multicenter trial to test whether the ARB valsartan could reduce the recurrence of atrial fibrillation. We enrolled patients who were in sinus rhythm but had had either two or more documented episodes of atrial fibrillation in the previous 6 months or successful cardioversion for atrial fibrillation in the previous 2 weeks. To be eligible, patients also had to have underlying cardiovascular disease, diabetes, or left atrial enlargement. Patients were randomly assigned to receive valsartan or placebo. The two primary end points were the time to a first recurrence of atrial fibrillation and the proportion of patients who had more than one recurrence of atrial fibrillation over the course of 1 year. RESULTS: A total of 1442 patients were enrolled in the study. Atrial fibrillation recurred in 371 of the 722 patients (51.4%) in the valsartan group, as compared with 375 of 720 (52.1%) in the placebo group (adjusted hazard ratio, 0.97; 96% confidence interval [CI], 0.83 to 1.14; P=0.73). More than one episode of atrial fibrillation occurred in 194 of 722 patients (26.9%) in the valsartan group and in 201 of 720 (27.9%) in the placebo group (adjusted odds ratio, 0.89; 99% CI, 0.64 to 1.23; P=0.34). The results were similar in all predefined subgroups of patients, including those who were not receiving angiotensin-converting-enzyme inhibitors. CONCLUSIONS: Treatment with valsartan was not associated with a reduction in the incidence of recurrent atrial fibrillation. (ClinicalTrials.gov number, NCT00376272.) 2009 Massachusetts Medical Society

Valsartan for prevention of recurrent atrial fibrillation

Recenze v:

Komentář [k článku Valsartan v léčbě fibrilace síní?].

000      
00000naa 2200000 a 4500
001      
bmc09002365
003      
CZ-PrNML
005      
20111210152437.0
008      
091105s2009 xr e cze||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a cze $b eng
044    __
$a xr
100    1_
$a Disertori, M.
245    10
$a Valsartan v léčbě fibrilace síní? / $c Disertori M, Latini R, Barlera S, Franzosi MG, Staszewsky L, Maggioni AP, Lucci D, Di Pasquale G, Tognoni G.
246    11
$a Valsartan for prevention of recurrent atrial fibrillation
520    9_
$a Atrial fibrillation is the most common cardiac arrhythmia, and no current therapy is ideal for control of this condition. Experimental studies suggest that angiotensin II-receptor blockers (ARBs) can influence atrial remodeling, and some clinical studies suggest that they may prevent atrial fibrillation. METHODS: We conducted a large, randomized, prospective, placebo-controlled, multicenter trial to test whether the ARB valsartan could reduce the recurrence of atrial fibrillation. We enrolled patients who were in sinus rhythm but had had either two or more documented episodes of atrial fibrillation in the previous 6 months or successful cardioversion for atrial fibrillation in the previous 2 weeks. To be eligible, patients also had to have underlying cardiovascular disease, diabetes, or left atrial enlargement. Patients were randomly assigned to receive valsartan or placebo. The two primary end points were the time to a first recurrence of atrial fibrillation and the proportion of patients who had more than one recurrence of atrial fibrillation over the course of 1 year. RESULTS: A total of 1442 patients were enrolled in the study. Atrial fibrillation recurred in 371 of the 722 patients (51.4%) in the valsartan group, as compared with 375 of 720 (52.1%) in the placebo group (adjusted hazard ratio, 0.97; 96% confidence interval [CI], 0.83 to 1.14; P=0.73). More than one episode of atrial fibrillation occurred in 194 of 722 patients (26.9%) in the valsartan group and in 201 of 720 (27.9%) in the placebo group (adjusted odds ratio, 0.89; 99% CI, 0.64 to 1.23; P=0.34). The results were similar in all predefined subgroups of patients, including those who were not receiving angiotensin-converting-enzyme inhibitors. CONCLUSIONS: Treatment with valsartan was not associated with a reduction in the incidence of recurrent atrial fibrillation. (ClinicalTrials.gov number, NCT00376272.) 2009 Massachusetts Medical Society
650    _2
$a financování organizované $7 D005381
650    _2
$a randomizované kontrolované studie jako téma $7 D016032
650    _2
$a blokátory receptorů AT1 pro angiotensin II $x terapeutické užití $7 D047228
650    _2
$a fibrilace síní $x epidemiologie $x farmakoterapie $x prevence a kontrola $7 D001281
650    _2
$a kardiomegalie $x epidemiologie $7 D006332
650    _2
$a kardiovaskulární nemoci $x epidemiologie $7 D002318
650    _2
$a komorbidita $7 D015897
650    _2
$a diabetes mellitus $x epidemiologie $7 D003920
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a proporcionální rizikové modely $7 D016016
650    _2
$a prospektivní studie $7 D011446
650    _2
$a recidiva $7 D012008
650    _2
$a tetrazoly $x terapeutické užití $7 D013777
650    _2
$a valin $x analogy a deriváty $x terapeutické užití $7 D014633
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Latini, R.
700    1_
$a Barlera, S.
700    1_
$a Franzosi, M. G.
700    1_
$a Staszewsky, L.
700    1_
$a Maggioni, A. P.
700    1_
$a Lucci, D.
700    1_
$a Di Pasquale, G.
700    1_
$a Tognoni, G.
773    0_
$w MED00012706 $t Clinical cardiology alert $g Roč. 3, č. 5 (2009), s. 38-39 $x 1213-2586
787    18
$w bmc09002366 $i Recenze v: $t Komentář [k článku Valsartan v léčbě fibrilace síní?]
910    __
$a ABA008 $b B 2242 $c 407 a $y 9
990    __
$a 20091105110109 $b ABA008
991    __
$a 20091201103525 $b ABA008
999    __
$a ok $b bmc $g 691536 $s 553435
BAS    __
$a 3
BMC    __
$a 2009 $b 3 $c 5 $d 38-39 $i 1213-2586 $m Clinical Cardiology Alert $x MED00012706
LZP    __
$a 2009-34/mkme

Find record

Citation metrics

Archiving options